Department of Cell Techniques and Applied Stem Cell Biology, Center of Biotechnology and Biomedicine, University of Leipzig, Deutscher Platz 5, D-04103 Leipzig, Germany.
Am J Sports Med. 2010 Sep;38(9):1857-69. doi: 10.1177/0363546510365296. Epub 2010 May 27.
The use of mesenchymal stem cells (MSCs) to treat osteochondral defects caused by sports injuries or disease is of particular interest. However, there is a lack of studies in large-animal models examining the benefits of chondrogenic predifferentiation in vitro for repair of chronic osteochondral defects.
Chondrogenic in vitro predifferentiation of autologous MSCs embedded in a collagen I hydrogel currently in clinical trial use for matrix-associated autologous chondrocyte transplantation facilitates the regeneration of a chronic osteochondral defect in an ovine stifle joint.
Controlled laboratory study.
The optimal predifferentiation period of ovine MSCs within the type I collagen hydrogel in vitro was defined by assessment of several cellular and molecular biological parameters. For the animal study, osteochondral lesions (diameter 7 mm) were created at the medial femoral condyles of the hind legs in 10 merino sheep. To achieve a chronic defect model, implantation of the ovine MSCs/hydrogel constructs was not performed until 6 weeks after defect creation. The 40 defects were divided into 4 treatment groups: (1) chondrogenically predifferentiated ovine MSC/hydrogel constructs (preMSC-gels), (2) undifferentiated ovine MSC/hydrogel constructs (unMSC-gels), (3) cell-free collagen hydrogels (CF-gels), and (4) untreated controls (UCs). Evaluation followed after 6 months.
With regard to proteoglycan content, cell count, gel contraction, apoptosis, compressive properties, and progress of chondrogenic differentiation, a differentiation period of 14 days in vitro was considered optimal. After 6 months in vivo, the defects treated with preMSC-gels showed significantly better histologic scores with morphologic characteristics of hyaline cartilage such as columnarization and presence of collagen type II.
Matrix-associated autologous chondrocyte transplantation with predifferentiated MSCs may be a promising approach for repair of focal, chronic osteochondral defects.
The results suggest an encouraging method for future treatment of focal osteochondral defects to prevent progression to osteoarthritis.
利用间充质干细胞(MSCs)治疗运动损伤或疾病引起的骨软骨缺损特别受关注。然而,目前缺乏大动物模型研究体外软骨分化预诱导对慢性骨软骨缺损修复的益处。
目前正在临床试验中使用的胶原 I 水凝胶中自体 MSC 的体外软骨分化预诱导,有利于羊膝关节慢性骨软骨缺损的再生。
对照实验室研究。
通过评估几种细胞和分子生物学参数,确定羊 MSC 在 I 型胶原水凝胶中的最佳体外预诱导分化期。对于动物研究,在 10 只美利奴羊后腿股骨内侧髁处造成骨软骨病变(直径 7mm)。为了建立慢性缺损模型,在创建缺损 6 周后才植入羊 MSC/水凝胶构建体。40 个缺损分为 4 个治疗组:(1)软骨分化预诱导的羊 MSC/水凝胶构建体(preMSC-gels),(2)未分化的羊 MSC/水凝胶构建体(unMSC-gels),(3)无细胞胶原水凝胶(CF-gels)和(4)未处理对照(UCs)。6 个月后进行评估。
就蛋白聚糖含量、细胞计数、凝胶收缩、细胞凋亡、压缩性能和软骨分化进展而言,体外分化 14 天被认为是最佳时间。体内 6 个月后,preMSC-gels 治疗的缺损显示出更好的组织学评分,具有透明软骨的形态特征,如柱状排列和存在 II 型胶原。
与预分化 MSCs 相关的基质内自体软骨细胞移植可能是修复局灶性慢性骨软骨缺损的一种有前途的方法。
结果表明,这是一种有前途的治疗局灶性骨软骨缺损的方法,可防止进展为骨关节炎。